12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Company News  |  Other News

Intellect Neurosciences, Pfizer neurology news

Intellect Neurosciences filed a suit in the New York State Supreme Court alleging that Pfizer breached a license deal covering Intellect's Antisenilin mAb platform technology. In May, the U.S. Patent and Trademark Office granted Intellect a patent covering Antisenilin mAbs that bind to beta amyloid while sparing the amyloid precursor protein (APP)...

Read the full 257 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >